ライフサイエンスコーパス: Fc fragment

1 family of Fab-like fragment relative to the Fc fragment.

2 he Calpha2-Calpha3 interdomain region in the Fc fragment.

3 antennae in mCrry-Ig were extended from the Fc fragment.

4 itis B virus (HBV) e antigen fused to an IgG Fc fragment.

5 at the C terminus of each heavy chain in the Fc fragment.

6 n CD24 connected to immunoglobulin G1 (IgG1) Fc fragment.

7 structure of EndoS in complex with the IgG1 Fc fragment.

8 of the omalizumab-Fab in complex with an IgE-Fc fragment.

9 composition of the immunoglobulin G1 (IgG1) Fc fragment.

10 in one F(ab')2 molecule and one homodimeric Fc fragment.

11 measurements for 77 peptide sequences of the Fc fragment.

12 us type-2 (HSV-2) glycoprotein gD, to an IgG Fc fragment.

13 perties of sc-gAd further, we fused it to an Fc fragment.

14 ialylation of the N-linked glycan of the IgG Fc fragment.

15 ct molecule, suggesting participation of the Fc fragment.

16 inge region, which joins the two Fab and one Fc fragments.

17 s of the hinge peptide joining the mCrry and Fc fragments.

18 on the anti-inflammatory activity of IVIG or Fc fragments.

19 "closed" anti-inflammatory state of antibody Fc fragments.

20 nicity, and yields therapeutic F(ab')(2) and Fc fragments.

21 hinge lysine 222 residue, generating Fab and Fc fragments.

22 preparation of appropriately sialylated IgG Fc fragments.

23 -inflammatory activity of IVIG or sialylated Fc fragments.

24 ain at position 222, generating free Fab and Fc fragments.

25 tructures for the CR2 SCR 1-2 and mouse IgG1 Fc fragments.

26 pes, with 64 residues connecting the Fab and Fc fragments.

27 cFv-C(H)3 dimer; 80 kDa) and a modified scFv-Fc fragment (105 kDa), designed to clear rapidly, were g

28 or as a fusion protein with the murine IgG2a Fc fragment (47-LDA-Fcgamma2a) to deliver the antigenic

29 pen V-shape in random orientations about the Fc fragment accounted for the scattering and sedimentati

30 GFR2/Ad Flk1-Fc), a control murine IgG2alpha Fc fragment (Ad Fc), or vehicle (phosphate-buffered sali

31 o be very similar to those of the free human Fc fragment, although differences are present in the ter

32 four-domain Fab fragments and a four-domain Fc fragment analogous to that in immunoglobulin G (IgG),

33 display peptide which binds a human antibody Fc fragment and creating a backbone cyclic beta-hairpin

34 ngineered as a fusion between the human IgG1 Fc fragment and the I(KACh) inhibitor tertiapinQ (TP), a

35 These modified Fc fragments and antibodies present strong potential to

36 tecting weak binding between full-length IgG/Fc fragments and Fc receptors and the effect of chemical

37 observed at the N-terminal residues of some Fc fragments and were identified as isocyanate and alpha

38 allowing us to engineer an appropriate IgG1 Fc fragment, and thus generate a fully recombinant, sial

39 bodies against IL6, soluble glycoprotein 130 Fc fragments, and the signal transducers and activators

40 fied the solution arrangement of its Fab and Fc fragments, and thereby its hinge structure.

41 erapeutic intravenous gamma globulin and its Fc fragments are anti-inflammatory.

42 The corresponding Fab+Fc fragment beginning with cys-218 was not found.

43 In addition, FREB lacks bona fide Fc fragment binding regions and does not bind immunoglob

44 artigimod, a first-in-class novel human IgG1 Fc fragment, binds the neonatal Fc receptor with high af

45 ies have defined the conformation of the IgE Fc fragment bound to the FcepsilonRIalpha ectodomain and

46 Killing was prevented by DcR3-Fc fragment but not control human-Fc fragment, showing t

47 tion time, for example, rapid removal of the Fc fragment by IdeS digestion, minimizes assay artifacts

48 l modification of nanobodies and an antibody Fc fragment by N- and C-terminal trans-splicing with sho

49 The IgG1 Fc fragments containing complex sialylated glycans attac

50 g both male and female mice, compared to the Fc fragment control.

51 d IgA1 hinge structures to which the Fab and Fc fragments could be connected in any orientation.

52 antibodies in the hinge region resulting in Fc (fragment crystallizable) and F(ab')(2) (fragment ant

53 residues on the N-linked glycans of the IgG Fc (fragment crystallizable) domain.

54 ubpicomolar affinity for IL-6, combined with Fc (fragment crystallizable) engineering to enhance phar

55 The antibody Fc (fragment crystallizable) region is a vital component

56 Here we engineered the receptor-binding Fc (fragment crystallizable) region of an antibody recog

57 n BALB/c mice, followed by treatment with an Fc (fragment crystallizable)-modified mIgG2a mouse anti-

58 ring the antibody binding fragment (Fab) and Fc (fragment, crystallizable) receptor region for therap

59 We administered CSF1-Fc (fragment, crystallizable) to mice after partial hepa

60 ect plaque erosion using (64)Cu-labeled GPVI-Fc (fragment crystallized).

61 eering technology is a powerful tool for IgG Fc (fragment cystallizable) N-glycosylation remodeling.

62 is observation, phage display of mutagenized Fc fragments derived from a human IgG1 was used to incre

63 erodimeric and homodimeric "knob" and "hole" Fc fragments derived from bacterial expression.

64 protein containing RBD linked to human IgG1 Fc fragment (designated RBD-Fc) induced high titer of RB

65 Fc fragments did not modulate any of these parameters.

66 gartigimod (ARGX-113), a human IgG1 antibody Fc fragment engineered to reduce pathogenic IgG autoanti

67 as a target for Ag delivery using engineered Fc fragment-epitope fusions.

68 ory activities through the engagement of its Fc fragment (Fc) with distinct Fcg receptors (FcgRs).

69 Recent studies have demonstrated that IgG-Fc fragments (Fcabs) can be engineered to form antigen-b

70 ation and lysosomal shuttling of IgM via its Fc fragment (Fcmu).

71 The protection was mediated by the Fc fragment functions of MR228.

72 ic NMO-IgG, preventing cytotoxicity, and the Fc fragments generated by IdeS cleavage reduced CDC and

73 ti-coagulant activity, small oligosaccharide fCS fragments had much reduced anticoagulant properties,

74 Efgartigimod alfa, a human IgG1 antibody Fc fragment, has demonstrated efficacy and safety in pat

75 The Fc fragments have distinct binding properties for FcRn t

76 sed of hepatitis B surface protein and IgG2a Fc fragment (HBS-Fc-lv) to increase the magnitude of CD8

77 mise the relative arrangement of the Fab and Fc fragments held in a fixed orientation resembling that

78 Characteristic Fab and Fc fragment immobilized patterns served as controls.

79 revealed that, compared with HBS-lv without Fc fragment, immunization with HBS-Fc-lv markedly increa

80 pendent of FcgammaRIIb or sialylation of the Fc fragment in the human setting.

81 By comparison, the structure of the Fc fragment in the IgM monomer is similar to that of the

82 the increased C1q binding to galactosylated Fc fragments in human polyclonal IgG.

83 structure of the arrangement of the Fab and Fc fragments in IgA2m(1) was found to be predominantly T

84 olution structure arrangement of the Fab and Fc fragments in IgD is principally T-shaped and flexible

85 Treatment with this omalizumab-resistant IgE-Fc fragment, in combination with omalizumab, promotes th

86 lpha ligands through injection of PDGFRalpha-Fc fragments, inhibit the migration of mesoderm cells af

87 eptidase, cleaves human IgG into F(ab')2 and Fc fragments inhibiting complement-dependent cytotoxicit

88 ch that the end-to-end distance of the bound Fc fragment is greater than it is in the crystal structu

89 Sialylation of the Fc fragment is mediated by beta-galactoside alpha2,6-sia

90 that generally does not require the antibody Fc fragment, likely plays an important role in the prote

91 les contain glycans in the CH2 domain of the Fc fragment (N-glycosylation) which are highly heterogen

92 the similar SpA B domain in complex with the Fc fragment of a human IgG antibody, where helix 3 is no

93 omain of a receptor, an enzyme, etc.) to the Fc fragment of a monoclonal antibody.

94 SCR 1-2 domain pair was engineered with the Fc fragment of a mouse IgG1 antibody to create a chimaer

95 f one such nanobody, X0, in complex with the Fc fragment of afucosylated IgG1.

96 which bind immunoglobulins (Ig) such as the Fc fragment of human IgG (IgG Fc) in a nonimmune manner.

97 fic binding of the recombinant enzyme to the Fc fragment of human IgG, a characteristic that may play

98 reversible interactions of protein A and the Fc fragment of human IgG, detection limits were determin

99 c receptor (FcgammaRIIIB) in complex with an Fc fragment of human IgG1 determined from orthorhombic a

100 The hinge region on the Fc fragment of human immunoglobulin G interacts with at

101 ood system is the avian equivalent of FCAMR (Fc fragment of IgA and IgM receptor).

102 lity complex class II T-cell epitopes in the Fc fragment of IgG that are capable of specifically acti

103 The interaction between a SpA domain and the Fc fragment of IgG was partially elucidated previously i

104 nts between the B domain (Fb) of SpA and the Fc fragment of IgG were identified from the x-ray crysta

105 tly related to FcgammaRI (receptor I for the Fc fragment of IgG) and is encoded on human chromosome 1

106 cRn-mediated transcytosis was blocked by the Fc fragment of IgG, but not F(ab')(2).

107 ll spread of virus and is a receptor for the Fc fragment of IgG.

108 groups that binds with high affinity to the Fc fragment of IgG.

109 III (FVIII) product that when fused with the Fc fragment of IgG1 results in significantly prolonged h

110 , N-, or P-cadherin ectodomains fused to the Fc fragment of immunoglobulin (E-cad/Fc, N-cad/Fc, and P

111 Receptors for the Fc fragment of immunoglobulin G (Fc gammaRs) play a cruc

112 rystal structure for the complex between the Fc fragment of immunoglobulin G (IgG) and the neonatal F

113 Certain Escherichia coli strains bind the Fc fragment of immunoglobulin G (IgG) at the bacterial c

114 Sialylated forms of the Fc fragment of immunoglobulin G, produced by the human a

115 factor VIII (rFVIII) product fused with the Fc fragment of immunoglobulin G1 (IgG1) in 165 patients

116 ated tridecasaccharide 1 associated with the Fc fragment of intravenous immunoglobulin has been synth

117 macrophages act as innate "sensors" for the Fc fragment of IVIG, leading to the induction of Fc gamm

118 Crry with five SCR domains conjugated to the Fc fragment of mouse IgG1 (mCrry-Ig) in order to determi

119 tion in IgG/FcRn binding based on changes in Fc fragment of the Abs.

120 recently showed that interaction between the Fc fragment of the broadly neutralizing antibody IgG1 b1

121 directly by LC-MS, while monkey IgG and the Fc fragment of the recombinant human IgG remained bound

122 ditional intracerebroventricular infusion of Fc fragment of tyrosine kinase receptor B protein (TrkB-

123 The Fc fragments of both human and sheep immunoglobulin G (I

124 Mice injected with IgA1P (1-10 mg/kg) had Fc fragments of IgA1 in both serum and urine, associated

125 The E-domain binds tightly to Fc fragments of IgG and binds certain Fv fragments with

126 Fc fragments of IgG were as active as IgG1, whereas Fab

127 F(ab')2 but not Fc fragments of IVIG induced death of human neutrophils,

128 ntained contiguous fH domains 18-20 fused to Fc fragments of murine IgG2a.

129 ceptor (FcR)-expressing leukocytes that bind Fc fragments of tAb.

130 the NK-cell surface, as only the immobilized Fc-fragment of GG was required for CD137 expression.

131 impact of FcRn binding characteristics of an Fc fragment on in vivo persistence allows this property

132 ull-length IgE with omalizumab-resistant IgE-Fc fragments on human basophils.

133 The inserted Fc fragments or antibodies can efficiently activate NK c

134 t neither binding nor penetration depends on Fc fragments or their cognate receptors.

135 Briefly, Fc fragments or therapeutic monoclonal antibodies are co

136 re studies of fCS-selectin interaction using fCS fragments or their mimetics may open new avenues for

137 se (IdeS) cleaves human IgG into F(ab')2 and Fc fragments, potentially inhibiting ADCC.

138 oinsulin fused with the immunoglobulin (Ig)G Fc fragment (PPI-Fc) is delivered to fetuses through the

139 iodinated minibody and a radioiodinated scFv-Fc fragment produced excellent, high-contrast images in

140 s on the engagement of microglia through the Fc fragment, providing critical insights for optimizing

141 pression of the high-affinity immunoglobulin-Fc fragment receptor I (FcgammaRI) CD64 on neutrophils (

142 Fc fragments released from HIRs-Fc by papain digestion a

143 hy/mass spectrometry analysis of the Fab and Fc fragments revealed several modifications.

144 the gas-phase unfolding, and CIU patterns of Fc fragments, revealing increased resistance of sialylat

145 ed by DcR3-Fc fragment but not control human-Fc fragment, showing that apoptosis occurs via the LIGHT

146 Fcupsilon3-4 is the only nonmammalian Fc fragment structure determined to date and provides th

147 Instead, we find elevation of a Fab+Fc fragment that began with aspartic acid (cleavage betw

148 his structural data to generate a mutant IgE-Fc fragment that is resistant to omalizumab binding.

149 In this work, modified antibodies or their Fc fragments that can target solid tumors without the ne

150 In contrast to the IgE Fc fragment, the IgE Fc in intact IgE is significantly l

151 protein of a complement receptor and an IgG Fc fragment, therapeutic outcome was improved in vivo.

152 Addition of TNF-alphaR fused to IgG Fc fragment (TNF-alphaR:Fc) in the presence or absence o

153 The targeting of a glycosylated antibody Fc fragment to bind to cancer cells by site-selective in

154 Although efficient binding of the IgG Fc fragment to cellular FcgammaRs may be essential to ac

155 These data show that modification of the Fc fragment to enhance ADCC can be an effective strategy

156 We also fused V1V2 to an Fc fragment to mimic the unconstrained V1V2 conformation

157 omplement C1q binding (Fc-/-) domains of the Fc fragment to render the Fc unable to direct Ab-depende

158 ng array in which FcRn dimers are bridged by Fc fragments to create an "oligomeric ribbon" with a 2n:

159 in mice between the binding affinity of IgG1/Fc fragments to FcRn at pH 6.0 and their serum t(1/2).

160 hemically coupling three synthetic mouse IgE-Fc fragments to plant-derived immunologically optimized

161 ective doses of intact antibody or monomeric Fc fragments to wild-type or Fcgamma receptor-humanized

162 fused to the human immunoglobulin G1-derived Fc fragment under the control of the beta-PHASEOLIN seed

163 affinities of a deglycosylated IgG1 and its Fc fragment were determined by solution binding studies

164 The two SCR domains and the Fc fragment were joined by randomised conformational pep

165 es, to which homology models for the Fab and Fc fragments were connected to generate 10,000 full mode

166 es, to which homology models for the Fab and Fc fragments were connected.

167 scein antibody (4-4-20) and antibody Fab and Fc fragments were immobilized from solution onto respect

168 nstrained by homology models for the Fab and Fc fragments were used to model the experimental IgA1 sc

169 ugar residues and amino acid residues in the Fc fragment, which in turn may impact antibody effector

170 employ IdeS protease to produce F(ab')2 and Fc fragments, which resulted in baseline resolution of t

171 ression system, we generated an IgG1-derived Fc fragment with a C-terminal selenocysteine in yields c

172 We show that engineered Fc fragments with increased affinities for FcRn at pH 6.

173 n of labeled IgG with an excess of unlabeled Fc fragment yielded a small yet significant increase in